<DOC>
	<DOCNO>NCT02634827</DOCNO>
	<brief_summary>This phase II trial study well midostaurin decitabine work treat old patient newly diagnose acute myeloid leukemia FLT3 mutation . Midostaurin decitabine may stop growth cancer cell block enzymes need cell growth .</brief_summary>
	<brief_title>Midostaurin Decitabine Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia FLT3 Mutation</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine complete response rate elderly patient FLT3 mutate acute myeloid leukemia ( AML ) use midostaurin decitabine . SECONDARY OBJECTIVES : I . Determine 1-year overall survival ( OS ) progression free survival ( PFS ) rate . II . Determine overall response rate patient treated regimen . III . Determine complete response duration patient treat regimen . IV . Assess safety toxicity regimen base National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0 . TERTIARY OBJECTIVES : I. Assess prognostic predictive factor ( FLT3 internal tandem duplication [ ITD ] versus [ v ] tyrosine kinase domain [ TKD ] mutation ) patient treat regimen . II . Explore genetic target disease . OUTLINE : Patients receive decitabine intravenously ( IV ) 1 hour day 1-5 midostaurin orally ( PO ) twice daily ( BID ) day 8-21 course 1 2 , day 1-28 subsequent course . Patients fail achieve complete response ( CR ) /complete response incomplete recovery ( CRi ) /partial response ( PR ) /morphologic leukemia-free state end course 2 receive midostaurin PO BID day 1-28 . Patients achieve CR/CRi/PR/morphologic leukemia-free state end course 8 may continue current regimen . Patients fail achieve CR/CRi/PR/ morphologic leukemia-free state bone marrow blast end course 8 go event monitoring . Treatment repeat every 28 day 18 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 month 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>4'-N-benzoylstaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>Unfit chemotherapy base investigator assessment patient willing receive intensive induction advise investigator Untreated , histological confirm acute myeloid leukemia ( AML ) base World Health Organization ( WHO ) 2008 criterion either/or : FLT3 ITD mutation FLT3 TKD mutation Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 , 2 3 Serum amylase lipase = &lt; 1.5 x upper limit normal ( ULN ) Total bilirubin = &lt; 1.5 x ULN ( apply patient isolate hyperbilirubinemia [ e.g. , Gilbert 's disease ] , case direct bilirubin = &lt; 2 x ULN ) Alkaline phosphatase = &lt; 3 x ULN Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) = &lt; 2.5 x ULN Creatinine = &lt; 2 x ULN Negative pregnancy test do = &lt; 7 day prior registration , woman childbearing potential Provide inform write consent Willing return consent Mayo Clinic ( Mayo Clinic 's campus Rochester ) , followup Active Monitoring Phase study Willing provide bone marrow aspirate blood sample correlative research purpose Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose 3 month treatment completion Highly effective contraception method include : Total abstinence ( line prefer usual lifestyle subject ; NOTE : periodic abstinence [ e.g. , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method contraception ) Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) tubal ligation least six week take study treatment ; case oophorectomy alone , reproductive status woman confirm follow hormone level assessment Male sterilization ( least 6 month prior screen ) ; NOTE : female subject study vasectomized male partner sole partner subject Combination two follow ( a+b a+c , b+c ) : ) Use oral , injected implant hormonal method contraception form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception b ) Placement intrauterine device ( IUD ) intrauterine system ( IUS ) c ) Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository NOTE : In case use oral contraception woman stable pill minimum 3 month take study treatment Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) OR Sexually active male unless use condom intercourse take drug 5 month stop midostaurin medication NOTE : They father child period A condom require use also vasectomize men order prevent delivery drug via seminal fluid Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimen Immunocompromised patient ( relate use corticosteroid ) include patient confirm human immunodeficiency virus ( HIV ) positive active viral hepatitis Uncontrolled intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement ; patient know concurrent severe and/or uncontrolled medical condition ( except carcinoma insitu ) , could compromise participation study ( e.g . uncontrolled infection , uncontrolled diabetes , chronic active pancreatitis ) Receiving investigational agent would consider treatment primary neoplasm Other active malignancy = &lt; 1 year prior registration ; EXCEPTIONS : nonmelanotic skin cancer carcinomainsitu cervix Previous treatment specific chemotherapy ( cytarabine , idarubicin , daunorubicin ) hypomethylating drug ( decitabine azacitidine ) hematological disorder ; EXCEPTIONS : prior hydroxyurea allow ; secondary AML allow Impaired cardiac function include follow : Inability monitor QT interval electrocardiogram ( ECG ) Congenital long QT syndrome know family history long QT syndrome Clinically significant rest brachycardia ( &lt; 50 beat per minute ) Corrected QT ( QTc ) &gt; 450 msec baseline ECG ; NOTE : ECG show QTc interval great 450 msec screen triplicate perform , one minute apart confirm find ( replacement electrolyte imbalance ) ; 2/3 3/3 ECGs confirm QT prolongation ( i.e . QTc interval &gt; 450 msec ) patient must include trial Myocardial infarction = &lt; 3 month prior start study Other clinically significant uncontrolled heart disease ( e.g . unstable angina , congestive heart failure uncontrolled hypertension ) History presence clinically significant ventricular , atrial tachyarrhythmias ejection fraction cutoff Left ventricle ejection fraction &lt; 45 % History congestive heart failure require use ongoing maintenance therapy lifethreatening ventricular arrhythmias Patients currently receive treatment strong cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) inhibitor treatment either discontinue switched different medication prior start study drug ; patient receive medication substance strong inhibitor CYP3A4 ; azoles fluconazole discourage used patient require treatment antifungal antibiotic ; use follow strong inhibitor prohibit = &lt; 7 day prior registration Strong inhibitor CYP3A4/5 ; &gt; 5fold increase plasma area curve ( AUC ) value 80 % decrease clearance Boceprevir ( Victrelis ) Clarithromycin ( Biaxin , Biaxin XL ) Conivaptan ( Vaprisol ) Indinavir ( Crixivan ) Itraconazole ( Sporanox ) Ketoconazole ( Nizoral ) Lopinavir/Ritonavir ( Kaletra ) Mibefradil Nefazodone ( Serzone ) Nelfinavir ( Viracept ) Posaconazole ( Noxafil ) Ritonavir ( NovirÂ® , Kaletra ) Saquinivir ( Fortovase , Invirase ) Telaprevir ( Incivek ) Telithromycin ( Ketek ) Voriconazole ( Vfend ) Troleandomycin Cobicistat Tipranavir Receiving medication substances inducer CYP3A4 ; use follow inducer prohibit = &lt; 7 day prior registration Strong inducer CYP3A4/5 ; &gt; 80 % decrease AUC Avasimibe Carbamazepine ( Carbatrol , Epitol , Equetro , Tegretol , TegretolXR ) Phenytoin ( Dilantin , Phenytek ) Rifampin ( Rifadin ) St. John 's wort Mitotane Rifabutin Phenobarbital Moderate inducer CYP3A4/5 ; 5080 % decrease AUC Bosentan ( Tracleer ) Efavirenz ( Sustiva ) Etravirine ( Intelence ) Modafinil ( Provigil ) Nafcillin Genistein Ritonavir Talyiraline Thioridazine Tipranavir Nevirapine ( Viramune ) Phenobarbital ( Luminal ) Rifabutin ( Mycobutin ) Troglitazone Patients currently receive treatment medication potential prolong QT interval treatment either discontinue switched different medication prior start study drug ; NOTE : prohibit medication contains drug use caution due possible conditional risk Torsades de Pointes Impaired gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection gastric bypass surgery ) Acute chronic pancreatic disease Known cytopathologically confirm central nervous system ( CNS ) infiltration Acute chronic liver disease severe renal disease consider unrelated cancer History significant congenital acquire bleed disorder unrelated cancer Major surgery = &lt; 4 week prior registration study recover prior surgery regardless time since surgery Treatment investigational agent = &lt; 30 day 5 halflives registration Diagnosis AMLM3 ( acute promyelocytic leukemia )</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>